1 / 49

Management of HIV/TB Co-infection

Management of HIV/TB Co-infection. Dr.G.Manoharan Medical Director, International Training and Education Center for Health India Clinical Associate Professor, DGH,UW. Topics to be discussed . When to start ART in HIV associated Tuberculosis Duration of TB treatment

garnet
Download Presentation

Management of HIV/TB Co-infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of HIV/TB Co-infection Dr.G.Manoharan Medical Director, International Training and Education Center for Health India Clinical Associate Professor, DGH,UW.

  2. Topics to be discussed • When to start ART in HIV associated Tuberculosis • Duration of TB treatment • Intermittent Vs Daily TB treatment • Drugs used in the TB Treatment • Recurrent TB/Relapse/Re-infection • Role of steroids

  3. Case study • 35 yrs. male HIV +VE • Hospitalized for weight loss, fever, and cough with expectoration • Diagnosed as sputum negative pulmonary TB, oral candidiasis and HIV wasting. • CD4 cell count- 70 cells & 18.3% Chest x-ray : 29th May, 04.

  4. Case study • OI s managed appropriately • Managed with ATT ( 2HREZ and 4RH), ART ( ddI,3TC and EFV) along with CTZ and Vitamins • Followed up regularly for almost an year

  5. Chest x-ray : 29th May, 04. Chest x-ray : 20th Sept, 04.

  6. Chest x-ray : Feb 05. Chest x-ray : June, 05.

  7. TB therapy in patients with HIV-TB Co-infection Aims of TB therapy are to • Achieve cure and prevent death • Prevent relapse • Render patients non-infectious as rapidly as possible • Prevent the emergence of drug resistance.

  8. TB therapy in patients with HIV-TB Co-infection So to achieve our aim, we need to • kill the actively metabolizing TB bacilli (Isoniazid) • destroy less actively replicating bacilli in the acidic and anoxic closed lesions(Pyrazinamide) • kill near-dormant bacilli that might otherwise cause a relapse of the disease (Rifampin)

  9. TB therapy in patients with HIV-TB Co-infection So the Anti TB drugs are given as • Initial Intensive phase followed by a • Continuous Phase

  10. TB therapy in patients with HIV-TB Co-infection 1. When will you start ART in patients with HIV-TB Co infection? 2. Do you give 6 months therapy or 9 months therapy? 3.Do you treat with intermittent regimen or daily Regimen? 4. What drugs do you use? Rifampin throughout the therapy? 5.What to do after the completion of ATT?

  11. 1 .When to Start Antiretroviral Therapy in HIV- TB co-infection Early ART IRIS Drug Toxicity Drug interactions High pill burden Delayed ART AIDS related Illness Mortality

  12. Studies: Early Vs Late initiation of ART • The Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPIT) trial • The AIDS Clinical Trials Group Study A5221 • The Cambodian Early versus Late Introduction of Antiretrovirals (CAMELIA) study N Engl J Med 365;16 october 20, 2011

  13. SAPiT Trial: Main Findings • Integrated therapy associated with 56% reduction in risk of death Vs sequential therapy Integrated therapy independently associated with reduced risk of death (HR: 0.43; 95% CI: 0.25-0.77; P = .004)

  14. SAPiT: Increased survival with concurrent HIV and TB treatment 1.00 Early ART Sequential ART 0.95 0.90 Survival 0.85 0.80 Intensive phase of TB treatment Post-TB treatment Continuationphase of TB treatment 0.75 0.70 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Months Postrandomization Abdool Karim SS, et al. CROI 2009. Abstract 36a.

  15. CAMELIA trial N Engl J Med, Vol 365;1No 6 ; october 20, 2011; Pages 1471-1481

  16. At wk 50, the median gain in the CD4 count was 118 in the earlier-ART group and 112 in the later-ART group (P = 0.22). whereas Viral load was undetectable in 96.5% of pts, with no difference between the two study groups (P = 0.82),

  17. CAMELIA trial : Early initiation of ART (2 weeks after the start of tuberculosis therapy) significantly increases survival among HIV infected adults with newly diagnosed tuberculosis and CD4+ T-cell counts of 200 per cubic millimeter or lower. This is of particular relevance in resource-limited settings where tuberculosis is the leading cause of death in HIV-infected patients

  18. Duration of TB treatment 2. TB therapy in patients with HIV-TB Co infection 6 Months Vs 9 Months or longer…..

  19. 6 months supervised intermittent TB therapy in patients with and without HIV- Haiti • Short-course, thrice-weekly therapy highly efficacious in HIV positive and HIV negative patients • 427 Patients ; 177 HIV +VE Ref: Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, Davis H, Boulos R, Quinn TC, Halsey NA. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV. Am J RespirCrit Care Med 1996;154:1034–1038.

  20. Ref: El-Sadr WM, Perlman DC, Denning E, et al. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001; 32: 623–632.

  21. Outcome of 6 Vs 9 Months anti-TB treatment in HIV-associated tuberculosis (without ART) • Antiretroviral treatment–naïve, HIV-Positive patients with TB, a 9-month regimen resulted in a similar outcome at the end of treatment but a significantly lower bacteriological recurrence rate compared with a 6-month thrice-weekly regimen. ARR was high with these intermittent regimens and neither mortality nor ARR was altered by lengthening TB treatment. ARR > Acquired Rifamycin Resistance Reference: Am J RespirCrit Care Med Vol 181. pp 743–751, 2010

  22. (2EHRZ3/4RH3) Vs (2EHRZ3/7RH3) Sputum culture negativity in months

  23. Kaplan-Meier plot showing time to death for patients in the 6-month regimen(blue line) and in the 9-month regimen (green line); P = 0.17 (not significant)..

  24. Time to bacteriological recurrenceup to 36 months for patients in the 6-month and 9-month regimen 9 Months Regimen P = 0.03 6 Months Regimen

  25. 6 Months Vs 9 Months Therapy A retrospective review from the US showed no treatment failures in HIV-1 infected patients administered a 6 month standard rifampicin-based regimen but relapse rates were four-times higher in those treated for 6 months compared to those treated for longer. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J RespirCrit Care Med 2007; 175: 1199–1206.

  26. Duration of TB therapy • Overall most studies concur that standard TB treatment should be given to HIV-1 infected patients whenever possible . • A 6-month treatment regimen that includes rifampicin and INH throughout should be given for drug-sensitive TB (outside of the central nervous system). This is usually a regimen of four drugs for 2 months, followed by INH and rifampicin for a further 4 months.

  27. Duration of ATT • Current recommendations: Standard 6-month regimens and the extension of therapy to 9 months for patients with extra pulmonary disease or a delayed response. • NACO guideline: Recommended to follow RNTCP guideline. Guidelines for Prevention and Management of Common Opportunistic Infections/Malignancies among HIV-Infected Adult and Adolescent, May 2007; NACO. The Journal of Infectious Diseases 2007; 196 : S35-45 ; BHIVA treatment guidelines for TB/HIV infection, February 2005.

  28. 3. TB therapy in patients with HIV-TB Co infection Intermittent Dosing /Therapy Vs Continuous therapy

  29. Contraindicated • Once weekly INH and Rifapentine • Twice weekly Rifampin- or Rifabutin- based regimens

  30. Pooled estimates of outcomes stratified by schedule of treatment administration during the initial intensive phase ( first 8 weeks)

  31. Intermittent Dosing ( ATT) • Current recommendations: In patients who have advanced immunodeficiency daily or three times weekly treatment for at least the first two months of intensive therapy. • NACO guideline: Recommend intermittent ( three times weekly ) regimen( as per RNTCP guideline) for all patients The Journal of Infectious Diseases 2007; 196 : S35-45

  32. 4. TB therapy in patients with HIV-TB Co infection What drugs? What drugs do you use? Rifampin throughout the therapy?

  33. Randomized controlled Trial of two 8-month regimens- a non inferiority study Ref: Results at 30 months of a randomized trial of two 8-month regimens for the treatment of tuberculosis: A.J. Nunn et al, Int J Tuberc Lung 15(6):741-745, 2011

  34. Status at 30 months by treatment arm and HIV status Ref: Results at 30 months of a randomized trial of two 8-month regimens for the treatment of tuberculosis: A.J. Nunn et al, Int J Tuberc Lung 15(6):741-745, 2011

  35. Treatment of Active Tuberculosis in HIV-TB Coinfected Patients: A systematic Review and Meta-Analysis.

  36. Recurrence / relapse after the completion of Anti TB Therapy The role post treatment INH

  37. 5. TB therapy in patients with HIV-TB Co infectionRecurrence / Re-infection • In Brazil, TB recurrence rates were high in HIV-1 infected persons but if there was completion of initial TB therapy, use of ART and subsequent increases in CD4 cell counts then recurrence rates were low, suggesting re-infection may have been the reason for recurrence . Ref: Golub JE, Durovni B, King BS, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008; 22: 2527–2533.

  38. Recurrence of TB after completing Rx

  39. Strategies to Reduce Recurrence Rates • 80% recurrences in HIV+: Re-infection • 90% recurrences in HIV-: Reactivation • Extending treatment (RH2 up to 12 months ↓ recurrence to 1.9% compared to 9%. • Post-treatment isoniazid prophylaxis for one year ↓ recurrence (1.4%/year) vs placebo (7.8%/ year) • HAART Ref: Sonnenberg Lancet 2001; Penneris NEJM 1995;Fitzgerald DW Lancet 2000

  40. 233 patients treated for TB Randomized Recurrence rate of TB in HIV+ and HIV- after therapy and Effect of Post-treatment Isoniazid HIV+ (142) HIV- (91) Placebo (74) Isoniazid (68) Placebo (40) Isoniazid (51) • Recurrent TB 12 2 0 1 • Recurrence rate per 100 persons-years (95% CI) 7.8 (4.1-13.3) 1.4 (0.0-3.4) 0.0 (0.0-4.0) 0.7 (0.0-3.9) Ref: Fitzgerald D, Desvarieux M, Sévère P, Joseph P, Johnson WD Jr, Pape J.W. The Lancet 2000 356 : 1470-74

  41. Effect of Post Treatment Isoniazid Prophylaxis on TB Recurrence Among HIV+ PatientsKaplan-Meier estimate of proportion of patients withrecurrent tuberculosis among HIV-1-positive individuals

  42. Additional Slides

  43. Am J RespirCrit Care Med Vol 167. pp 603–662, 2003

  44. Benefit of Cotrimoxazole therapy in HIV-TB co infected patients • Studies in Coˆ te d’Ivoire & Malawi >> significant decrease in mortality and the number of hospital admissions & improved survival • In a large study in Uganda >> The effect on mortality was seen only among patients with CD4 cell counts < 200 cells/mm3 or with WHO stage 3 or 4 HIV disease, but the reductions in morbidity were seen among all HIV-infected patients (1) Wiktor SZ et al ; Lancet 1999; 353:1469–75.(2) Mwaungulu FB et al. Bull World Health Organ 2004; 82:354–63.(3) Mermin J, et al, Lancet 2004; 64:1428–34.

  45. Adjunctive Therapy • Immunomodulatorsincluding corticosteroids, therapeutic vaccines, and other drugs and biologics—have the potential to shorten TB treatment by modulating the host response and helping the immune system to eliminate persistent organisms. (1) ImperialiFG et al ; ClinExp Immunol; 2001; 123:435–42. (2)Ehlers S et al ; J Rheumatol Suppl 2005; 74:35–9. (3) Keane J et al ; Rheumatology2005; 44:714–20. (4) Wallis RS et al ; J Infect Dis1996; 174:727–33. (5)Wallis RS et al ; AIDS2004; 18:257–64. (6)Bekker LG et al ; J Infect Dis2000; 181:954–65. (7) Smego RA et al ; IntJ TubercLung Dis2003; 7:208–13.

  46. Role of Steroids in the management of HIV-TB co infection • In HIV-1-infected adults with pulmonary or pleural TB, corticosteroids do not improve survival or reduce TB recurrence [1-3]. • A sub study of HIV-1 infected persons within a randomised controlled trial of dexamethasone for TBM in Vietnam showed a trend towards increased survival in the dexamethasone arm [4]. • Most physicians, therefore, give steroids to patients with TB meningitis and use dexamethasone 12–16 mg?day-1 intravenously until the patient begins taking medicines orally. • An alternative is prednisolone 1.5 mg?kg-1?day-1 for 3 weeks and tapered over the next 3 weeks [5]. • A randomised controlled trial of adjunctive prednisolone in HIV-1-infected patients with effusive tuberculouspericarditis demonstrated reduction in mortality among patients who received prednisolone despite the relatively small sample size (n558) [3].

  47. Thank you • ITECH India/Arogyaan express our gratitude and thanks to Lucie Kroschel and Alex McGee for their logistic support.

More Related